insulin glulisine + recombinant human hyaluronidase PH20

A combination of **insulin glulisine**, a rapid-acting recombinant human insulin analog, and **recombinant human hyaluronidase PH20 (rHuPH20)**, an enzyme that temporarily degrades hyaluronan at the subcutaneous injection site to accelerate drug absorption. This combination is designed to **accelerate the pharmacokinetics of insulin glulisine**, enabling faster onset and increased absorption compared to insulin glulisine alone. The accelerated absorption aims to provide better post-prandial (mealtime) glycemic control in diabetes by mimicking the physiological profile of endogenous insulin more closely. Primary development is focused on improving glycemic control for patients with **type 1 and type 2 diabetes**. Halozyme Therapeutics leads development, targeting an improved, ultra-fast insulin formulation for subcutaneous use[1][2][3][4].

Other names

insulin glulisine + rHuPH20glulisine + recombinant human hyaluronidase PH20recombinant human hyaluronidase PH20 + insulin glulisine